Antiplatelet Drugs Market - Snapshot

At times wrongly referred to as ‘blood thinning’ drugs, products in global antiplatelet drugs market actually assist in dealing with the blood clots. These drugs decrease the clumping blood cells by decreasing harmful blood clots. Products in the global antiplatelet drugs market are also used to treat patients undergoing complex surgical procedures such as angioplasty. Rising elderly population and rapidly changing lifestyles are witnessed contributing to the increasing prevalence of heart disorders around the world. For instance, WHO or World Health Organization estimates that approximately 15 million people each year are suffering from a heart condition such as heart strokes. These factors are expected to factor the growth of global antiplatelet drugs market in coming years.

A major restraint for global antiplatelet drugs market is the rising risk associated with bleeding in extremely complex surgeries. Side effects caused by the products in global antiplatelet drugs market may include symptoms such as upset stomach, diarrhea, itching, nausea, rash, and stomach pain. These side effects are also impeding the growth of global antiplatelet drugs market. Misconception that antiplatelet drugs are blood thinning drugs is also one of the barriers for the global antiplatelet drugs market. On the other hand, rising instances of cardiovascular diseases such as rheumatic heart disease, inflammatory heart disease, cerebrovascular heart disease, hypersensitive heart disease, and ischemic heart disease is also expected to motivate the global antiplatelet drugs market in coming years.

Global Antiplatelet Drugs Market: Overview

Globally, the number of people suffering from ischemic strokes has increased, especially in developed countries. People suffering from myocardial infarction and stent thrombosis have also gone up. The use of antiplatelet drugs helps in reducing the ability of platelets to stick together and obstructs blood clots formation that leads to these diseases. Thus, its demand has grown significantly in the past few years.

Advancement in pharmaceuticals, proliferation of anticoagulant/antithrombotic drugs, and rising thrombolytic events are the key drivers for the antiplatelet drugs market. Antiplatelet drugs help in effective arterial circulation and are widely used in the primary and secondary prevention of cardiovascular or thrombotic cerebrovascular disorders.

The global antiplatelet drugs market could be classified on the basis of disease type, drug class, and distribution channel. Based on distribution channel, the market is segmented into online pharmacies, retail pharmacies, and hospital pharmacies. Based on drug class, the market is segmented into platelet aggregation inhibitors, glycoprotein platelet inhibitors, and protease-activated receptor-1 antagonists.

The report provides a detailed description of the global antiplatelet drugs market. It provides information focusing on the drivers, restraints, trends, and opportunities affecting the growth of the market. Furthermore, regional analysis with key segment analysis derived through facts and figures is also presented in the report.  

Global Antiplatelet Drugs Market: Trends and Opportunities

According to the data provided by the American Heart Association, there are about 800,000 individuals suffer from stroke every year in the U.S. among these three out of four-experience stroke the very first time. Of these, 87% are ischemic strokes. Moreover, based on the data provided by the Centers for Disease Control and Prevention, 735,000 people have a heart attack in Latin America and North America. Of these 525,000 people experience heart attack the very first time. Thus, the growing trend of these diseases has led to the growth of the antiplatelet drugs market.  

Global Antiplatelet Drugs Market: Geographic Analysis

Regions taken into consideration while analyzing the growth of the antiplatelet drugs market are Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. Among these regions, in 2016, North America held the larger share in the market. A large number of patients suffering from myocardial infarction led to the dominance of this region. In the same year, Europe held the second position in the market due to the rise in research and development on antiplatelet drugs. On the other hand, Asia Pacific market is expected to grow at a significate rate owing to rising government initiatives to reduce the number of deaths caused by stent thrombosis, ischemic stroke, and myocardial infarction.

Global Antiplatelet Drugs Market: Competitive Landscape

The competitive landscape given in the report on the global antiplatelet drugs market provides detail description about the prominent players operating in the market. Leading players in the market are implementing advanced business development strategies to get a strong hold in the global market. Sanofi, Otsuka Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., AstraZeneca, and Boehringer Ingelheim GmbH are some of the prominent players operating in the market.

Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Antiplatelet Drugs Market